What Spasgan Treats: Main Uses and Benefits

Spasgan may be part of symptomatic management in situations where patients experience distressing symptoms, and is relevant in contexts marked by increased discomfort or tension. This medication is commonly used across conditions involving episodic or fluctuating manifestations, and may assist with symptoms linked to organ-specific functional stress. The therapeutic profile of Spasgan is relevant for easing symptoms of increased neurological or muscular activity and associated discomfort.

Easing Episodes of Sudden Discomfort

Spasgan is applied in clinical settings that involve acute or unstable symptom patterns, or when symptoms associated with acute or episodic changes may appear suddenly or intensify temporarily. It helps address symptom clusters that interfere with daily comfort, and is used in areas where short-term symptom management is appropriate.

Supporting Management and Daily Comfort

This medication is applied in clinical settings that involve acute or unstable symptom patterns, helping to improve day-to-day comfort during symptomatic periods. A general benefit is that it supports patients during episodes of heightened discomfort and may assist with maintaining functional stability.

Quick Fact: Relief for Symptoms related to Physical Discomfort

Who Can and Cannot Use Spasgan?

Regulatory labeling establishes clear eligibility boundaries for the use of Spasgan (Sodium Metamizole, Pitofenone, Fenpiverinium Bromide). The medicine is contraindicated for several specific populations.

Absolute Prohibitions (Contraindicated)

Spasgan must not be used by individuals with a known hypersensitivity to the active ingredients or to related pyrazolone derivatives. Use is also strictly prohibited in patients with pre-existing impaired haematopoiesis (such as a history of agranulocytosis), acute hepatic porphyria, or severe gastro-intestinal obstruction. The medicine is contraindicated for infants below three months of age or under 5 kg of body weight, and for women in the third trimester of pregnancy.

Restricted and Conditional Use

The fixed-dose combination is not recommended for children younger than 15 years of age. Use is advised against during the first and second trimesters of pregnancy and is not recommended for women who are breastfeeding. Furthermore, official labeling requires conditional use for populations with pre-existing mild to moderate renal or hepatic impairment, and caution may be necessary for older adults with compromised organ function.

Spasgan is a medication used to relieve muscle spasms, often formulated as a combination product containing an antispasmodic agent, such as drotaverine, and a non-steroidal anti-inflammatory drug (NSAID), such as mefenamic acid (often referred to as Spasgan-M). Due to its components, specific drug-drug interactions are clinically significant and require careful attention.

Potential Drug Interactions

General Considerations

The anti-spasmodic component may interact with medicines that also have anticholinergic effects, potentially increasing side effects like dry mouth or dizziness. Additionally, alcohol consumption should be avoided with this medicine, as it may enhance side effects such as drowsiness and dizziness. It is critical to inform your healthcare provider about all prescription drugs, over-the-counter products, and herbal supplements currently being used.

️ How Spasgan Works

The action of this combination product is achieved by engaging three distinct pharmacological mechanisms across two key physiological systems: nociceptive signaling and smooth muscle contraction. This coordinated effect involves both central and peripheral modulation.

Dual Antispasmodic Action on Smooth Muscle

This peripheral domain influences the involuntary contraction cascade through two complementary pathways. Fenpiverinium Bromide employs a neurotropic mechanism by blocking muscarinic receptors, thereby interrupting the nerve signal that initiates smooth muscle contraction. Simultaneously, Pitofenone provides a direct myotropic effect by blocking Ca^2+ channels, physically preventing the necessary calcium influx required for the muscle fiber to tense. This dual blockade results in a reduction of involuntary smooth muscle tone, which is the physiological consequence.

Central Modulation of Nociceptive Pathways

The analgesic component, Sodium Metamizole, operates primarily within the Central Nervous System ( CNS) to modulate nociceptive processing. Its mechanism involves the central inhibition of the COX-3 enzyme to reduce PGE2 synthesis, and the modulation of the body's intrinsic opioidergic and cannabinoid ( CB1) pain control systems. This activity alters the CNS's pain threshold and reduces the sensitivity of central nociceptive pathways.

Official Administration Guidelines

Spasgan, the fixed-dose combination of Sodium Metamizole, Pitofenone, and Fenpiverinium Bromide, is authorized for two official routes of administration: oral (tablet form) and parenteral via intramuscular (IM) injection. Treatment with the oral formulation is strictly limited to a short-term duration and should not exceed three days. The injectable form is also reserved for short-term use, typically for 2–3 days.

Standard Posology and Frequency

The standard oral adult dose (age 15 years and older) is typically one to two tablets per dose, taken two to three times daily. The established maximum authorized daily dose for the oral formulation is six tablets. For the parenteral route, administered under strict medical control, the IM single dose ranges from 2 to 5 mL of the solution, with a maximum daily limit of 6 mL. The IM dose may be repeated after 6 to 8 hours if required.

Administration Context and Adjustments

Tablets are explicitly instructed to be taken by mouth with water after eating (with food). For specific patient groups, the regimen is adjusted; lower, age-specific doses are defined for children aged 9 to 15 years. Furthermore, official prescribing information advises a potential reduction of the adult dose by half (1/2) for patients with mild to moderate kidney impairment, and high doses are to be avoided in liver impairment. If an oral dose is missed, patients should continue with the next scheduled dose and must not take a double dose to compensate.

Research Evidence / Overview of Studies for Spasgan

Evidence for Use in Acute Visceral Spasms (Colic Pain)

The research base for Spasgan, the fixed-dose combination (FDC) of Sodium Metamizole, Pitofenone, and Fenpiverinium Bromide, is relevant in trials assessing short-term or episodic symptom patterns and was studied in research contexts involving pain linked to smooth muscle hyperactivity, particularly acute pain associated with smooth muscle spasm, such as that seen in renal or biliary colic. Studies exploring this use typically include short-term randomized controlled trials (RCTs) and comparative studies, often focusing on Metamizole-based formulations alongside the combination of two spasmolytic components. These trials were conducted using adult populations experiencing acute, disruptive episodes of pain.

Research examined the measurement of outcomes related to physical discomfort, primarily focusing on the change in pain intensity recorded on standardized scales and the time elapsed before patients reported any modification of symptoms. Findings describe patterns observed in these acute settings, with evidence contributing to the broader landscape of how multi-component formulations are studied for pain where smooth muscle contraction is a key factor.

Evidence for Use in General Smooth Muscle Hyperactivity

Research also explored the use of the combination in managing general discomfort related to functional smooth muscle hyperactivity. This evidence includes data derived from observational settings, open-label clinical experience, and pharmacological studies. In these research scenarios, studies focused on episodes where symptoms become more noticeable, evaluating patient-reported outcomes describing perceived discomfort over defined, short time intervals. The evidence for this broader, functional indication is broadly characterized as Low to Moderate. Data is often extrapolated from studies addressing acute colic and is less robust than that for specific painful conditions.

Duration of Study and Follow-up

The available research focuses almost exclusively on short-term assessment of acute episodes, reflecting the nature of the condition it was studied for. Because the FDC was evaluated in studies exploring acute or episodic pain symptoms, long-term outcomes are not well characterized by dedicated trials. There is limited information for long-term outcomes, and research exploring symptomatic patterns of continuous use is scarce.

How to Store and Dispose of Spasgan

The storage and disposal of Spasgan must strictly follow the official instructions provided on the regulatory label to maintain its stability and safety.

Storage Requirements

Spasgan must be stored at a temperature below 25 C and kept out of the sight and reach of children. To prevent degradation, the product requires protection from light and moisture and should be kept in its original container or package. The injection form must not be frozen. The medicine should not be used after the expiry date.

Disposal Instructions

Official regulations prohibit the disposal of this medicine in wastewater or household waste. For proper discarding of unused or expired Spasgan, patients should ask a pharmacist about local authorized medicine take-back programs.